Dr. Schoder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10021Phone+1 212-639-7373
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Nuclear Medicine, 1998 - 2000
- Humboldt University of Berlin - Charite Faculty of MedicineClass of 1989
Certifications & Licensure
- NY State Medical License 2000 - 2026
- CA State Medical License 2000 - 2025
- NJ State Medical License 2006 - 2025
- American Board of Nuclear Medicine Nuclear Medicine
- CBNCNuclear Cardiology
Clinical Trials
- Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors Start of enrollment: 2005 Jun 01
- The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules Start of enrollment: 2004 Mar 01
- The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer Start of enrollment: 2006 Apr 25
- Join now to see all
Publications & Presentations
PubMed
- Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.Jennifer K Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman
Blood Cancer Journal. 2024-10-14 - 1 citationsF18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury.Shruti Gupta, Olivia Green-Lingren, Sudhir Bhimaniya, Aleksandra Krokhmal, Heather Jacene
The Journal of Clinical Investigation. 2024-08-08 - 5 citationsImaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly
The Lancet. Oncology. 2024-08-01
Journal Articles
- CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PETDavid J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood
Abstracts/Posters
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Heiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaHeiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple MyelomaHeiko Schoder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- The SNMMI and EANM Practice Guideline for Renal Scintigraphy in AdultsAugust 8th, 2018
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: